Measuring blood metabolites during electroconvulsive therapy for depression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to analyze changes in blood metabolites using 1H NMR spectroscopy at various time points during electroconvulsive therapy (ECT) in patients experiencing a major depressive episode. Participants will include individuals diagnosed with major depressive disorder or bipolar disorder who meet specific criteria for ECT treatment. Blood samples will be collected before and after the first session, as well as before the 6th, 12th, and final sessions of ECT, alongside assessments of depression severity and cognitive function. The goal is to explore whether metabolomic changes can predict treatment response and enhance understanding of ECT's biological mechanisms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Major depressive episode according to DSM-5 criteria
* Diagnosis of major depressive disorder or bipolar disorder
* MADRS score \>22
* having given written, free and informed consent
* without protective measures
* resistance criterion defined as failure of 2 antidepressants at an effective dose for a minimum of 6 weeks
* current major depressive episode according to DSM-5 criteria with indication of treatment by ECT cure

Exclusion Criteria - Cannot be included in the study, people:

* whose consent is not admissible or who refuse to participate in the study
* deprived of liberty by judicial or administrative decision
* For which there is a particular risk contraindicating the cure of ECT
* Suffering from schizophrenia spectrum disorders or persistent delusional disorder as described by DSM-5 Criterion D for Major Depressive Disorder
* suffering from neurological disorders (such as patients suffering from multiple sclerosis, epilepsy, encephalitis, etc.) and/or neurodegenerative disorders (such as Parkinson's disease, Alzheimer's disease or related diseases, etc.) as described by criterion C of the major depressive disorder listed in the DSM-5
* suffering from an acute or chronic systemic inflammatory disease requiring specific treatment with immunomodulators or suppressors. As well as any recurrent inflammatory disease requiring specific management, and which may lead to a differential diagnosis of the characterized depressive episode as described by criterion C listed in the DSM-5

Where it's running

• Centre Hospitalier le Vinatier
  Bron, France Recruiting

Study contacts

• Study coordinator: COSTEMALE-LACOSTE Jean-François, PH
• Email: jean-francois.costemale-lacoste@ch-le-vinatier.fr
• Phone: (0)4 37 91 54 95

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sensation Seeking and TMS Response in TRD: Does Personality Shape Treatment Outcomes?

  This real-world study tests whether people with treatment-resistant depression who have higher sensation-seeking traits respond differently to TMS treatment.

  Recruiting Technical University of Munich · München, Bavaria · NCT07889739

• Remote monitoring for adults with depression using ThIA Suivi

  This study tests whether adding the ThIA Suivi remote monitoring tool to usual psychiatric care helps adults with depression feel more improved after 3 months compared with standard care alone.

  Recruiting at 3 sites Phase 1 ThIA Santé Mentale · Bron and 2 other locations · NCT07878754

• EEG microstates and inflammatory markers in treatment-resistant depression patients undergoing ECT

  This study tests how electroconvulsive therapy affects brain activity patterns seen in EEG and inflammatory biomarkers in adults with treatment-resistant major depression.

  Recruiting Istanbul University - Cerrahpasa · Istanbul, Bakırköy · NCT07748091

• EEG microstates and inflammatory biomarkers in older adults with major depression receiving ECT

  This study tests how ECT affects brain wave patterns and inflammatory markers in people 55 and older with major depression.

  Recruiting Istanbul University - Cerrahpasa · Istanbul, Bakırköy · NCT07740694

• Flumazenil to help reduce cognitive side effects during ECT for depression

  This study tests whether giving flumazenil to reverse benzodiazepine effects during electroconvulsive therapy can lower cognitive side effects without reducing treatment effectiveness in adults with depression.

  Recruiting Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Frederiksberg, Capital Region · NCT07619092

• Sleep-to-Mood in Depression: Home-based tDCS

  This study tests whether home-based tDCS for adults with moderate depression helps sleep improve and whether better sleep is linked to mood improvements.

  Recruiting NYU Langone Health · New York, New York · NCT07572526

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.